Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome Medical Dialogues Bureau24 Jan 2020 6:01 AM GMTHod Hasharon: Wize Pharma a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed...
